Apellis Pharmaceuticals Inc EBITDA
Qual é o EBITDA de Apellis Pharmaceuticals Inc?
O EBITDA de Apellis Pharmaceuticals Inc é N/A
Qual é a definição de EBITDA?
O EBITDA é o lucro de uma empresa antes de juros, impostos, depreciação e amortização e é uma medida contábil calculada com base no lucro líquido de uma empresa, subtraído antes das despesas de juros, impostos, depreciação e amortização, como imagem da lucratividade operacional corrente de uma empresa.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
O que Apellis Pharmaceuticals Inc faz?
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.